Omnicell, Inc. (NASDAQ:OMCL) Receives $52.33 Consensus PT from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received a consensus rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $52.33.

A number of equities analysts have recently commented on OMCL shares. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. Benchmark reiterated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. Wells Fargo & Company lowered their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Finally, Bank of America lowered their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th.

Omnicell Stock Performance

Shares of Omnicell stock opened at $33.00 on Friday. The firm’s fifty day simple moving average is $40.71 and its 200-day simple moving average is $43.27. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of 122.23, a PEG ratio of 7.53 and a beta of 0.85. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities analysts forecast that Omnicell will post 1.09 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

Institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its position in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in Omnicell in the 4th quarter valued at about $37,000. Van ECK Associates Corp grew its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Omnicell in the 4th quarter valued at about $53,000. Finally, First Horizon Advisors Inc. grew its stake in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.